WuXi Biologics, China’s leading biologics medicine manufacturer, is to invest €325 million in a new biopharmaceuticals contract manufacturing facility in Dundalk, Co. Louth. Located mid-way between Dublin and Belfast, the facility will be less than an hour’s drive from Ireland’s two largest cities. This highly significant investment will provide a valuable employment boost for the region, leading to the creation of 400 jobs when in full production. The jobs at the facility will range from manufacturing to technical and quality assurance roles as well as associated administration positions. This represents WuXi Biologics’ first ever manufacturing investment in Europe and marks the company’s first investment of this scale anywhere outside of China. When complete, WuXi Biologics Ireland will be the world’s largest facility using single-use bioreactor technology.
As the Site Head, I am intensely proud that WuXi Biologics has chosen Ireland for such a major investment. This is a huge vote of confidence in this country.
Among the reasons for the decision were the availability of a highly educated and talented workforce, the existence of an established cluster of world-leading biopharmaceutical companies, a world-class research base and the availability of a shovel-ready greenfield site in Dundalk, which will enable the facility to be ready for production during 2021. All of us at WuXi Biologics eagerly await the challenge of developing this highly advanced new facility over the coming years. We look forward to becoming active members of the local business com.
IDA Ireland is committed to bringing foreign direct investment to the regions and its success in bringing WuXi Biologics to Dundalk reflects this policy. Located on the M1, halfway between Dublin and Belfast, Dundalk has easy access to ten leading higher education institutes, a highly qualified and skilled talent pool and is close to major international connections via Dublin Airport, Dublin Port and other ports along the east coast. In addition, the Dundalk site also had planning permission in place for a biologics facility.